Conclusion

Applicants believe that the subject matter of the pending claims is patentable and that the instant application should accordingly be allowed. If the Examiner believes that a conversation with Applicants' attorney would be helpful in expediting prosecution of this application, the Examiner is invited to call the undersigned attorney at (203) 812-6450.

Respectfully submitted,

Dated: October 5, 2004

Susan M. Pellegrino
Attorney for Applicants
Reg. No. 48,972

Bayer Pharmaceuticals Corporation
400 Morgan Lane
West Haven, CT 06516
(Tel) (203) 812-6450
(Fax) (203) 812-6459

Amendment to the Specification (Attorney Docket No. LeA 36 031)

Please amend the specification by inserting this paragraph on page 1, line 1 of the specification following the title:

This application is a 371 of PCT/EP03/03327, filed March 31, 2003.

Amended Claims (Attorney Docket No. LeA 36 031)

1. (Original) An aqueous formulation comprising (-)-(R)-3-(2-hydroxymethylindanyl-4-oxy)phenyl 4,4,4-trifluorobutane-1-sulfonate (I) and cyclodextrin.

2. (Original) A formulation as claimed in claim 1, comprising from 0.00005 to 9.0 g/l of the compound (I) and from 0.1 to 550 g/l of cyclodextrin.

3. (Currently amended) A formulation as claimed in claim 1 ~~either of the preceding claims~~, comprising from 0.0001 to 0.050 g/l of the compound (I) and from 0.2 to 200 g/l cyclodextrin.

4. (Currently amended) A formulation as claimed in claim 1 ~~any of the preceding claims~~, comprising from 0.0005 to 0.025 g/l of the compound (I) and from 1 to 50 g/l cyclodextrin.

5. (Currently amended) A formulation as claimed in claim 1 ~~any of the preceding claims~~, which has a pH of from 2 to 6.

6. (Currently amended) A formulation as claimed in claim 1 ~~any of the preceding claims~~, comprising at least one physiologically tolerated acid.

7. (Original) A formulation as claimed in claim 6, which comprises citric acid as physiologically tolerated acid.

8. (Currently amended) A formulation as claimed in claim 1 ~~any of the preceding claims~~, comprising from 8 to 10 g/l sodium chloride based on the formulation ready for use.

9. (Currently amended) A formulation as claimed in claim 1 ~~any of the preceding claims~~, comprising from 0.05 to 2 g/l ethanol based on the formulation ready for use.

10. (Currently amended) An administration kit consisting of

    a) a container comprising the aqueous formulation as claimed in claims 1 ~~to 9~~,

    b) infusion apparatus, where at least the parts which come into contact with the product consist of polyethylene, polypropylene, polyester, polyamide, acrylonitrile-butadiene-styrene copolymers, polypropylene/ styrene-ethylene-butylene-styrene or copolymers thereof.